Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Ustekinumab Injection bulk supplier for pharma manufacturers

Ustekinumab Injection Suppliers & Bulk Manufacturers

Available Forms: SQ and IV injection

Available Strengths: SQ:: 45 mg, 90 mg; IV: 130 mg/vial

Reference Brands: Stelara(US)

Category: Immune Disorder

Ustekinumab injection as 45 mg and 90 mg subcutaneous syringes and a 130 mg intravenous vial. An anti-IL-12/23 biologic listed for hospitals, specialist distributors and licensed importers with cold-chain capability.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Ustekinumab Injection? List it or send an offer →

Product Description:

Ustekinumab is a fully human IgG1 monoclonal antibody. It binds the p40 subunit that interleukin-12 and interleukin-23 share, so neither cytokine can signal through its receptor. This page covers both presentations. The subcutaneous 45 mg and 90 mg prefilled syringes are used for maintenance, often given by the patient or a nurse at home. The intravenous 130 mg vial, at 5 mg/mL, is used once as a weight-based induction infusion in inflammatory bowel disease.

Ustekinumab is approved for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In psoriasis, dosing is subcutaneous throughout: 45 mg, or 90 mg in heavier patients, at weeks 0 and 4, then every 12 weeks. In Crohn's disease and ulcerative colitis, one IV infusion, diluted in sodium chloride 0.9% and run over at least an hour, is followed by subcutaneous 90 mg maintenance. Tuberculosis screening comes first. Serious infection is the main precaution, and live vaccines are avoided during treatment.

Sourcing notes. This is a biologic and a true cold-chain product. Syringes and vials are stored at 2-8 °C, never frozen, in the carton to protect them from light. Ask for temperature-logged shipping in validated packaging and a written excursion policy. Registration follows the biologics pathway with a full CTD quality file, so check whether your market expects the reference product or accepts a biosimilar. Request the batch CoA, GMP certificate, CoPP and, where national rules require it, lot release evidence. State presentation, quantity, remaining shelf life on arrival and your biologics import licence.

Ustekinumab Injection — third party manufacturing & bulk supply

Ustekinumab Injection is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ustekinumab Injection is supplied as SQ and IV injection — supplied in more than one dosage form, each with its own manufacturing economics, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ustekinumab Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ustekinumab Injection →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Ustekinumab Injection is listed as SQ and IV injection in SQ:: 45 mg, 90 mg; IV: 130 mg/vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ustekinumab Injection is referenced against Stelara(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.

Related Products

Everolimus Tablets

Strength:
0.75 mg, 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg

Form: Tablet

Reference Brands: Zortress, Afinitor(US & EU)

View Details
Sirolimus Tablet

Strength:
1 mg, 2 mg, 3 mg, 5 mg tablets

Form: Tablet

Reference Brands: Rapamune(US)

View Details
Anakinra Injection

Strength:
100 mg/mL

Form: Injection(SQ)

Reference Brands: Kineret (US)

View Details
Cyclosporine Capsules

Strength:
25 mg, 50 mg, 100 mg

Form: Capsules

Reference Brands: Neoral, Sandimmune (US)

View Details
Remibrutinib

Strength:
25 mg

Form: Tablets

Reference Brands: -

View Details
Auranofin

Strength:
3 mg

Form: Capsules

Reference Brands: Ridaura (USA)

View Details
Deucravacitinib

Strength:
6 mg

Form: Tablet

Reference Brands: Sotyktu (USA/EU)

View Details
Fostamatinib Disodium

Strength:
100 mg, 150 mg

Form: Tablets

Reference Brands: Tavalisse (USA)

View Details
Enquire Now

Usually answered within 48 hours | GMP documents shared before you commit

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us